Aevitas Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Aevitas Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.16M	Buy	4,896 +169	+4%	+$36K	0.69%	39
2022 Q3	$946K	Hold	4,727	–	–	0.71%	42
2022 Q2	$689K	Sell	4,727 -730	-13%	-$104K	0.47%	60
2022 Q1	$891K	Hold	5,457	–	–	0.54%	53
2021 Q4	$925K	Hold	5,457	–	–	0.55%	53
2021 Q3	$1.03M	Hold	5,457	–	–	0.66%	42
2021 Q2	$925K	Hold	5,457	–	–	0.59%	49
2021 Q1	$770K	Buy	5,457 +40	+0.7%	+$6.02K	0.54%	53
2020 Q4	$704K	Hold	5,417	–	–	0.52%	54
2020 Q3	$789K	Sell	5,417 -500	-8%	-$71.1K	0.65%	43
2020 Q2	$876K	Sell	5,917 -715	-11%	-$96.4K	0.81%	35
2020 Q1	$722K	Hold	6,632	–	–	0.81%	36
2019 Q4	$764K	Hold	6,632	–	–	0.72%	38
2019 Q3	$533K	Sell	6,632 -157	-2%	-$12.4K	0.53%	56
2019 Q2	$493K	Sell	6,789 -200	-3%	-$15.3K	0.5%	59
2019 Q1	$653K	Sell	6,989 -157	-2%	-$13.1K	0.58%	48
2018 Q4	$521K	Sell	7,146 -100	-1%	-$7.69K	0.53%	54
2018 Q3	$634K	Hold	7,246	–	–	0.57%	50
2018 Q2	$714K	Sell	7,246 -300	-4%	-$29.8K	0.7%	43
2018 Q1	$899K	Sell	7,546 -300	-4%	-$38.7K	0.9%	36
2017 Q4	$997K	Buy	+7,846	New	+$986K	0.95%	37

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Aevitas Wealth Management's ALNY Position: Q4 2022 in Review

Aevitas Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 3.6% in Q4 2022, buying an estimated $36K and bringing the position to 4,896 shares worth $1.16M. The position accounts for 0.69% of the portfolio, ranked #39.

Aevitas Wealth Management first reported a position in ALNY in Q4 2017 and has held it in 21 quarters since. 487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

Aevitas Wealth Management held 4,896 shares of Alnylam Pharmaceuticals worth $1.16M as of Q4 2022.
Aevitas Wealth Management bought 169 Alnylam Pharmaceuticals shares in Q4 2022, an estimated $36K.
Alnylam Pharmaceuticals made up 0.69% of Aevitas Wealth Management's portfolio in Q4 2022, its #39 holding.
Aevitas Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2017 and has held it in 21 quarters since.
487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Aevitas Wealth Management's 13F filing for Q4 2022, filed 24 Jan 2023.